MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niznik, H. B.
Right arrow Articles by Seeman, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niznik, H. B.
Right arrow Articles by Seeman, P.

Dopamine D1 receptors of the calf parathyroid gland: identification and characterization

HB Niznik, EL Fogel, CJ Chen, D Congo, EM Brown and P Seeman

Department of Medicine, University of Toronto, Ontario, Canada.

The dopamine D1 receptor was identified in the calf parathyroid gland. The binding of the selective D1 receptor antagonist [3H]SCH-23390 to membranes of calf parathyroid was specific, reversible, and saturable with a dissociation constant of approximately 200 pM and a receptor density of 30 fmol/mg of protein. Dopaminergic agonists and antagonists inhibited [3H]SCH-23390 binding in a concentration-dependent and stereoselective manner with an appropriate pharmacological specificity for D1 dopamine receptors. Moreover, potent dopaminergic agonists recognized two affinity forms of the receptor, one displaying high affinity for agonists, termed D1 High, and one with low affinity, D1 Low. The addition of the nonhydrolyzable guanine nucleotide guanyl 5'- yl-imidodiphosphate caused the complete transition of the agonist high affinity form (D1 High) of the receptor to one displaying only low affinity for agonists (D1 Low). Sodium ions, however, caused a approximately 5-fold decrease in the affinity of agonists at both D1 High and D1 Low. Virtually identical results were obtained on D1 receptor preparations of neural origin. The D1 receptor identified here appears to be the one responsible for the physiological effects on the parathyroid gland, because dopamine-stimulated cAMP accumulation is stereoselectively blocked by the D1 receptor antagonist SCH-23390 in dispersed cells of the parathyroid gland. Moreover, a series of nine dopaminergic antagonists and agonists shows an excellent correlation between their potency in [3H]SCH-23390 binding assays and their corresponding effects on cAMP accumulation. In the case of agonists, Ka for activation of cAMP accumulation agrees most closely with the agonist low affinity site in binding experiments. Specific [3H]spiperone binding to D2 dopamine receptors was not detected in this tissue and as such, the calf-parathyroid gland provides a model system in which to study the molecular characteristics of dopamine D1 receptor- mediated events.

Volume 34, Issue 1, pp. 29-36, 07/01/1988
Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
C. N. Falany, J. L. Falany, J. Wang, J. Hedström, H. v. E. Chelpin, and S. Swedmark
Studies on Sulfation of Synthesized Metabolites from the Local Anesthetics Ropivacaine and Lidocaine Using Human Cloned Sulfotransferases
Drug Metab. Dispos., September 1, 1999; 27(9): 1057 - 1063.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
J. Wang, J. L. Falany, and C. N. Falany
Expression and Characterization of a Novel Thyroid Hormone-Sulfating Form of Cytosolic Sulfotransferase from Human Liver
Mol. Pharmacol., February 1, 1998; 53(2): 274 - 282.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1988 by the American Society for Pharmacology and Experimental Therapeutics